Do you want to read an article? Please log in or register.
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Related content
Lipid-Lowering Drugs
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial
JAMA Cardiol.
Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J
doi: 10.1001/jamacardio.
Heart, Artery and Coronary Diseases
Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults
JAMA Cardiol.
Björnsson E, Thorleifsson G, Helgadóttir A, Guðnason T, Guðbjartsson T, Andersen K, Grétarsdóttir S, Ólafsson Í, Tragante V, Ólafsson ÓH, Jónsdóttir B, Eyjólfsson GI, Sigurðardóttir Ó, Thorgeirsson G, Guðbjartsson DF, Thorsteinsdóttir U, Hólm H, Stefánsson K
doi: 10.1001/jamacardio.2019.2946.
Lipid-Lowering Drugs
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis
JAMA Cardiol.
Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP
doi: 10.1001/jamacardio.2018.2258
RECOMMENDED
Lipid-Lowering Drugs
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
Atherosclerosis.
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP
doi: 10.1016/
Heart, Artery and Coronary DiseasesThrombosis and Stroke
Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization Study
J Am Heart Assoc.
Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, INVENT Consortium., Tzoulaki I, Dehghan A
doi: 10.1161/JAHA.
Hypertension
Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension
JAMA Intern Med.
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ
doi: 10.1001/jamainternmed.
Lipid-Lowering DrugsTherapy and Intervention
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol.
Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS
doi: 10.1001/jamacardio.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial
JAMA Cardiol.
Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E
doi: 10.1001/jamacardio.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis.
Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L
doi: 10.1016/j.atherosclerosis.2020.07.006.